Novartis Pharmaceuticals

Why trials sponsored by Novartis Pharmaceuticals stopped, in this sample of ClinicalTrials.gov.

48 stopped trials with a clear reason; 79% ended for non-scientific reasons.

Where it ranks

• #5 of 90 sponsors by share of trials stopped for: funding or business decisions (56%).

Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.

Trials

• Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
  NCT07039422 · WITHDRAWN · safety
  “The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby reducing the likelihood of generating a sufficiently robust dataset to support reliable efficacy \& safety conclusions.”
• Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
  NCT05722522 · TERMINATED · funding business
  “Project discontinued to prioritize other key programs in portfolio”
• A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.
  NCT05524051 · TERMINATED · funding business
  “Sponsor Decision”
• Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension
  NCT05135000 · TERMINATED · funding business
  “Sponsor Decision”
• A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
  NCT05111249 · TERMINATED · safety
  “The trial was halted prematurely due to signs and symptoms that suggested the possibility of peripheral neuropathy. All participants who received branaplam continued to undergo routine (safety) evaluations for up to a year following their final dose”
• Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
  NCT04156659 · WITHDRAWN · funding business
  “This study was cancelled before enrolling any patients for business related reasons.”
• Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
  NCT04895202 · TERMINATED · slow accrual
  “Insufficient patient recruitment”
• Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India
  NCT05020873 · TERMINATED · funding business
  “sponsor decision”
• Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
  NCT04795466 · TERMINATED · funding business
  “Terminated by Sponsor”
• Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
  NCT04712721 · TERMINATED · funding business
  “Business reasons”
• Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis
  NCT04864392 · TERMINATED · funding business
  “Study early terminated due to lack of effect (did not meet primary/ secondary endpoints). This decision was not linked to safety concerns”
• Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants
  NCT04896632 · TERMINATED · funding business
  “Sponsor's decision.”
• Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
  NCT04079231 · WITHDRAWN · logistics pi
  “This study was cancelled due to COVID-19.”
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
  NCT04427072 · TERMINATED · funding business
  “Company decision not related to any safety concerns.”
• Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
  NCT04323436 · TERMINATED · funding business
  “Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies”
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
  NCT04181762 · TERMINATED · futility
  “Study terminated by sponsor due to futility analysis”
• HDM201 Added to CT in R/R or Newly Diagnosed AML
  NCT03760445 · WITHDRAWN · other
  “It was determined that the study design may not be optimal given the changing AML treatment landscape.”
• This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
  NCT03968419 · TERMINATED · slow accrual
  “Study early terminated due to low enrollment compared to the anticipated figures.”
• A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia
  NCT03874858 · TERMINATED · funding business
  “Sponsor decision: The primary endpoint of the core/TF1 was achieved, and the sample size of Extension/TFR2 was unlikely to yield meaningful results. No new safety signals were observed. For these reasons, continuing the study was not justified.”
• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects
  NCT03631199 · TERMINATED · funding business
  “Results of primary analysis showed addition of canakinumab to combination treatment did not improve tumor response or overall survival; the decision to stop the trial was not due to safety concerns”
• A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection
  NCT03369912 · WITHDRAWN · funding business
  “Company decision to withdraw before study started”
• Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
  NCT03529084 · WITHDRAWN · funding business
  “Decision by Sponsor not to continue with the trial.”
• LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)
  NCT03354754 · TERMINATED · funding business
  “The trial was closed as part of the out-licensure of the drug to Boston Pharmaceuticals, which will continue further clinical development of LYS228/BOS-228”
• Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
  NCT03301896 · TERMINATED · funding business
  “Business reasons”
• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
  NCT03287414 · TERMINATED · funding business
  “Sponsor decision”
• Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
  NCT03172936 · TERMINATED · funding business
  “Sponsor's decision”
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
  NCT03207867 · TERMINATED · funding business
  “Sponsor decision”
• PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
  NCT03064854 · TERMINATED · funding business
  “Recruitment halted prematurely due to competitive landscape for lung cancer therapies”
• Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
  NCT02873650 · TERMINATED · slow accrual
  “Study was terminated due to continued enrolment difficulties.”
• Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
  NCT02900651 · TERMINATED · funding business
  “The decision of early termination was made due to business reasons, and was not based on any safety or tolerability concerns for MAK683”
• Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients
  NCT02763644 · TERMINATED · slow accrual
  “LFG316, had been studied in seven patients with transplantation-associated microangiopathy. Due to low confidence of clinical benefit, this study was closed.”
• Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib
  NCT02115386 · TERMINATED · funding business
  “Study was terminated by Novartis”
• Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
  NCT02074995 · TERMINATED · slow accrual
  “The study was prematurely terminated due to recruitment issues”
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis
  NCT02038049 · TERMINATED · funding business
  “The study recruitment was terminated based on strategic considerations after 8 patients were enrolled.”
• ACZ885 for the Treatment of Abdominal Aortic Aneurysm
  NCT02007252 · TERMINATED · futility
  “The results of a third interim analysis (ad hoc) indicated a lack of efficacy and futility in continuing the trial.”
• A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.
  NCT01972776 · TERMINATED · safety
  “Part 1 was completed. Part 2 was terminated for safety reasons.”
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
  NCT01874340 · TERMINATED · funding business
  “Study terminated early based upon development of another anti-IL17 fully human monoclonal antibody with better potential for treating MS patients”
• Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma
  NCT01747876 · TERMINATED · futility
  “Lack of efficacy caused enrollment to be stopped at the end of dose escalation”
• Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
  NCT01566630 · TERMINATED · funding business
  “Novartis terminated this study due to internal, strategic decisions.”
• An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
  NCT01646125 · TERMINATED · futility
  “An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.”
• A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  NCT01602315 · TERMINATED · slow accrual
  “early termination due to Sponsor decision (slow recruitment)”
• Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
  NCT01459718 · TERMINATED · slow accrual
  “The study terminated due to low enrollment.”
• Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
  NCT01200589 · TERMINATED · futility
  “The study stopped due to futility.”
• LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
  NCT01034657 · TERMINATED · slow accrual
  “The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.”
• Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib
  NCT00644878 · TERMINATED · slow accrual
  “Slower than expected enrollment”
• Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
  NCT00601978 · WITHDRAWN · funding business
  “Business decision brand strategy; no patients enrolled”
• QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
  NCT00581997 · TERMINATED · safety
  “Concerns about risk of bronchoscopy procedure in the selected patient population and frequency of SAEs observed to date.”
• Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
  NCT00260208 · TERMINATED · slow accrual
  “Study was prematurely terminated due to poor recruitment.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.